Bayer and J&J initiate new trials to expand use of Xarelto
German drug major Bayer (BAYN: DE) and partner Janssen, a subsidiary of US health care giant Johnson & Johnson (JNJ), have expanding the clinical trial program of what is already the world’s most-studied oral anticoagulant, Xarelto A (rivaroxaban) with the aim of securing additional indications for the drug.
Xarelto, which is already approved and marketed for several indications (the most important being stroke prevention in patients with atrial fibrillation), generated sales of 322 million euros ($418 million) in 2012, and Bayer has forecast peak sales of 2 billion euros for the drug. However, there was a setback earlier this month, when the US Food and Drug Administration issued a second complete response letter regarding its supplemental New Drug Administration (sNDA) for Xarelto for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (The Pharma Letter March 5).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze